August 4, 2021 11:23 AM 23 seconds read

Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate

by Vandana Singh Benzinga Editor
Follow
Comments
  • The FDA has granted orphan drug designation to Aldeyra Therapeutics Inc's ALDX ADX-2191 to treat retinitis pigmentosa (RP).
  • ADX-2191 is a methotrexate for intravitreal injection.
  • Methotrexate inhibits dihydrofolic reductase, an enzyme involved in cellular replication and activation.
  • Price Action: ALDX shares are up 0.56% at $9 during the market session on the last check Wednesday.
  • Related content: Benzinga's Full FDA Calendar.
ALDX Logo
ALDXAldeyra Therapeutics Inc
$6.83-2.08%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum96.64
Growth-
Quality-
Value-
Price Trend
Short
Medium
Long
Overview
Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In:
BiotechNewsHealth CareSmall CapFDAGeneralBriefsOrphan Drug DesignationRetinitis Pigmentosa

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved